An interventional study of Eltrombopag in ITP - Immune Thrombocytopenia, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Sohag University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 with no phase, and was the 33rd registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 12–75
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University: 6 open now, 6 under way, none of them phase 3.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is one of 3 that started in 2025, is one of 5 with no phase, and was the 9th registered.
Sohag University’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2021.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sohag University’s 11 in Purpura, Thrombocytopenic, Idiopathic:
This tab as a report to print or save as PDF → With an account.
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver
Exclusion Criteria:
Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .
Drug: Eltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
the incidence and severity of liver dysfunction in ITP patients
Time frame: 3-6 months after receiving eltombopag
Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →